Pluripotent stem cells

#Drug discovery #Guide #iPSC #Macrophages #Pluripotent stem cells

Guide: Optimising macrophage differentiation from iPSCs

Facing challenges with macrophage differentiation from iPSCs? Discover valuable insights in this new Guide from Lonza: ‘Optimising Macrophage Differentiation from iPSCs with X-VIVO® Media.’ Get the guidance you need to overcome these obstacles to address challenges regularly faced by scientists, from drug discovery to QA/QC. Download the Guide for free… Read More

#News

#Drug discovery #iPSC #Macrophages #Pluripotent stem cells

Optimising macrophage differentiation from iPSCs with Lonza’s X-VIVO Media

Facing challenges with macrophage differentiation from iPSCs? Discover valuable insights in our mini review ‘Optimising Macrophage Differentiation from iPSCs with X-VIVO® Media.’ Get the guidance you need to overcome these obstacles to address challenges regularly faced by scientists, from drug discovery to QA/QC. Read More

#Resources

Neurons
#Biobanking #iPSC #Pluripotent stem cells #Stem cells

Advancing iPSC science through biobanking solutions

This advertorial for Sampled appeared in DDW Volume 26 – Issue 2, Spring 2025 Read the digital issue Some technologies are always ‘on the horizon’, but induced pluripotent stem cells (iPSCs) have finally arrived. Researchers can transform iPSCs into virtually any cell type, making them invaluable for disease modelling, drug… Read More

#Exclusive Content

#Axol Bioscience #Cell lines #iPSC #Mergers and acquisitions #Phenocell #Pluripotent stem cells

iPSC technology provider Axol Bioscience acquires Phenocell

Axol Bioscience has fully acquired Phenocell, though financial terms of the agreement were not disclosed. The acquisition extends Axol’s portfolio of iPSC-derived cell models, adding skin and human retinal iPSC-derived cell lines to its existing neuroscience, pain and touch, and cardiovascular products and services. Phenocell’s offering includes human iPSC-derived sebocytes… Read More

#Business & Investment #News

#bit bio #EU patent #iPSC #Patent Law #Pluripotent stem cells

bit.bio wins patent defence for opti-ox technology

bit.bio has successfully defended its foundational European patent for opti-ox, a technology the company says enables deterministic forward programming of pluripotent stem cells (PSCs). Following an anonymous opposition filed on 5 January 2023 and a public hearing on 25 September 2024, the European Patent Office’s (EPO) Opposition Division has confirmed… Read More

#Business & Investment #News

Pluripotent stem cells
#Cell therapy #Neuroscience #Pluripotent stem cells #Society for Neuroscience #Stem cells

Neuroscience 2024: Leveraging human stem cells to treat diseases

Progress in stem cell technologies is advancing powerful new ways of studying and treating formerly intractable neurological and neuropsychiatric diseases. Several interwoven examples have been discussed at Neuroscience 2024, the annual meeting of the Society for Neuroscience. Over 40% of the global population lives with some… Read More

#News #Trending News

Stem cells
#Diabetes #Phase I trial #Pluripotent stem cells #Stem cells #Type 1 diabetes

Stem cell therapy cures type 1 diabetes

A type 1 diabetes patient has been successfully treated using chemically induced pluripotent stem-cell-derived islets (CiPSC islets). The Phase I trial is the first ever example of a person with the disease being treated using cells that were extracted from their own body. The… Read More

#Editor's Choice #News

Neuron
#ALS #Human disease models #iPSC #Neurology #Pluripotent stem cells #Stem cells #Whitepaper

Whitepaper: Explore iPSC-derived motor neuron morphology

A new whitepaper is now available from DDW and Sartorius entitled ‘iPSC-Derived Motor Neurons and Microglia From ALS Background Display Disease Phenotype’. Induced pluripotent stem cell (iPSC)-derived cells are a significant resource for disease modelling. They allow the use of cells directly from affected patients… Read More

#News

#ALS #Drug discovery #Human disease models #iPSC #Neurology #Pluripotent stem cells #Stem cells

Using patient-specific cells for disease modelling

Induced pluripotent stem cell (iPSC)-derived cells are a significant resource for disease modelling. They allow the use of cells directly from affected patients and have the potential to guide these cells towards multiple lineages. Download the whitepaper to: Explore iPSC-derived motor neuron morphology Discover how ALS disease phenotype… Read More

#Resources

Stem cell transplant
#Cell therapy #Pluripotent stem cells #Regenerative Medicine #Stem cell transplant #Stem cells #University of Arizona

Genetically modified stem cells evade immune rejection

New research has brought stem cell transplantation without immune suppression closer to reality. Researchers at the University of Arizona Health Sciences say they are one step closer to understanding immunological rejection, a barrier to regenerative medicine, after genetically modifying pluripotent stem cells to evade immune recognition. Read More

#Editor's Choice #News